Parliamentary Search

Written question asked by Baroness Altmann (Conservative) on Monday, 30 January 2023, in the House of Lords. It was due for an answer on Monday, 13 February 2023. It was answered by Lord Markham (Conservative) on Monday, 20 February 2023 on behalf of the Department of Health and Social Care.

Coronavirus: Immunosuppression

Question

To ask His Majesty's Government what assessment they have made of the decision by regulatory authorities in the United States of America to disallow further use of the Evusheld monoclonal antibody product; and what steps they will take to ensure appropriate prophylaxis and treatment against COVID-19 for vulnerable immunodeficient and immunocompromised patients.

Answer

The Antivirals and Therapeutics Taskforce engages with other nations to share learning on the use, deployment and evaluation of therapeutics and antivirals. Evusheld (tixagevimab and cilgavimab) has a conditional marketing authorisation in the United Kingdom for the pre-exposure prophylaxis of COVID-19 and has been referred to the National Institute for Health and Care Excellence (NICE) to make recommendations for the National Health Service on whether it should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness.

The final outcome of NICE’s evaluation on the use of Evusheld as a pre-exposure prophylactic treatment against COVID-19 is expected in April 2023.

Secondary information

Type
Written question
Reference
HL5171
Session
2022-23
Related items
Coronavirus: Immunosuppression
Thursday, 2 March 2023
Written questions
House of Lords
Subjects
Drugs Coronavirus Immunosuppression Preventive medicine
Link
View this Written question on www.parliament.uk